Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Location: France, Ile-de-France
Employees: 11-50
Total raised: $71.83M
Founded date: 2014
Investors 5
| Date | Name | Website |
| 22.07.2021 | Seroba Lif... | seroba-lif... |
| - | V-Bio Vent... | v-bio.vent... |
| 25.11.2021 | Kurma Part... | kurmapartn... |
| 25.03.2022 | Turenne Ca... | turennecap... |
| - | GO Capital... | gocapital.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.01.2025 | Series A | $32.98M | - |
| 21.07.2021 | Series B | $38.84M | - |
Mentions in press and media 9
| Date | Title | Description |
| 09.01.2025 | Coave Therapeutics Raises €32M in Series A Financing | Coave Therapeutics, a Paris, France-based genetic medicines company, raised €32M in Series A funding. The round was led by Novo Holdings A/S and Bpifrance, with participation from Invus and UI Investissement, alongside existing investors Se... |
| 15.06.2023 | Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b. | Paris, France. 31 May 2023. Seroba portfolio company, Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces... |
| 20.09.2022 | Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders | Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders |
| 16.09.2021 | Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa | Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa |
| 22.07.2021 | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform |
| 21.07.2021 | Coave raises $25M ahead of pivotal retinal gene therapy trial Eight Technological 'Must Haves' to Support Your Decentralized Clinical Trial | Coave Therapeutics has added €21.2 ($25.0 million) million to its series B round, setting the French biotech up to move a gene therapy against PDE6b inherited retinal dystrophies toward pivotal trials. Seroba Life Sciences led the series B ... |
| 21.07.2021 | Coave Therapeutics Closes €33M in Series B Financing | Coave Therapeutics, a Paris, France-based clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, raised a €21.2m ($25.1m) expansion of its Series B f... |
| - | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform. | Paris, France – 21st July 2021. • Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases • Funding led by Seroba Life Sciences and suppo... |
| - | Coave Therapeutics | “Coave Therapeutics – Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.” |